Immune

PNC27

Also known as: PNC-27, p53-HDM2 Disruptor Peptide, Anti-Cancer Peptide PNC-27

Preclinical
Share:

Key Facts: PNC27

Category
Immune
FDA Status
Not FDA Approved
Clinical Status
Preclinical - Extensive in vitro studies, ex vivo human cancer tissue studies
Administration
IV injection in animal studies - not for human use
Typical Dose
No human dose - research compound only
Frequency
Not applicable - no human use
Duration
Research protocols only - no human use data
Also Known As
PNC-27, p53-HDM2 Disruptor Peptide, Anti-Cancer Peptide PNC-27

Mechanism of Action

The hook is selectivity. Many cancer cells display the protein HDM-2 (the human version of MDM2) on their outer membrane, while most normal cells keep it tucked inside. PNC-27 carries the part of p53 that normally docks onto HDM-2, so it latches onto that membrane-bound HDM-2 on cancer cells. Once anchored there, the peptide's amphipathic helix-loop-helix structure inserts into the membrane and forms pores, causing the cell to rupture and die by necrosis rather than the slower apoptosis pathway. The peptide has also been reported to disrupt mitochondrial membranes after entering the cell. Normal cells that lack membrane HDM-2 are reported not to bind the peptide and survive, which is the basis for the selectivity claim.

Research Summary

The mechanistic story is backed by real peer-reviewed work, most notably a 2010 paper in PNAS (Sarafraz-Yazdi and colleagues) showing PNC-27 adopts an HDM-2-binding shape and kills cancer cells by binding HDM-2 in their membranes, plus a 2010 study confirming the intact peptide causes tumor cell lysis. Follow-up work, including a 2022 paper in Biomedicines, reinforced the membrane-pore model and selectivity in cell lines and showed transfecting membrane HDM-2 into normal cells makes them vulnerable too. Crucially, all of this is in vitro and in animal models. There are no completed human clinical trials demonstrating safety or anticancer benefit in patients, so any claim that PNC-27 treats cancer in people is not supported. It is a genuinely intriguing preclinical anticancer concept that has not crossed into proven human therapy, and self-experimentation is not justified by the data.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

Dosing Information

Animal Studies·Extensive in vitro research, ex vivo human cancer tissue studies, limited animal studies

Note: Animal study doses may not translate directly to humans.

Typical Dosing

Community experience

Common Dose

No human dose - research compound only

Range

Lab research: 0.1-0.3 mg/mL in cell culture

Frequency

Not applicable - no human use

Experimental anti-cancer peptide with strong lab evidence but NO human clinical trials. Research shows 0.2-0.3 mg/mL kills 90-100% of cancer cells in vitro while sparing normal cells. Only tested in cell cultures and ex vivo tissue samples. Not available through peptide vendors - strictly a research compound for cancer biology studies.

Research Dosing

Scientific studies

Lab concentrations from peer-reviewed studies - no human dosing established

Duration

Research protocols only - no human use data

Administration

IV injection in animal studies - not for human use

Timing & Administration

Best Time to Take

Per research protocol

Research protocols only

Food Recommendation

With or without food

Why This Timing?

Experimental compound with short half-life. In vitro studies show optimal activity at 37°C with peptide re-addition every 24 hours.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Limited safety data - research compound only
  • Highly selective for cancer cells in vitro
  • No cytotoxicity observed in normal cells (fibroblasts, leukocytes)
  • Temperature-dependent activity (37°C optimal, minimal at 17°C)
  • Not tested in human clinical trials
  • Unknown systemic effects in humans
  • Potential immunogenicity unknown

References

Research This Peptide Further

Frequently Asked Questions

What does PNC27 do?

PNC-27 is a 32-amino-acid lab-designed peptide that fuses a fragment of the tumor-suppressor protein p53 (residues 12 to 26) to a membrane-penetrating leader sequence. The interesting claim is that it kills cancer cells while leaving normal cells alone, by punching holes in the cancer cell membrane. It is a research compound only, with no approval and no human clinical trials.

How does PNC27 work?

The hook is selectivity. Many cancer cells display the protein HDM-2 (the human version of MDM2) on their outer membrane, while most normal cells keep it tucked inside. PNC-27 carries the part of p53 that normally docks onto HDM-2, so it latches onto that membrane-bound HDM-2 on cancer cells. Once anchored there, the peptide's amphipathic helix-loop-helix structure inserts into the membrane and forms pores, causing the cell to rupture and die by necrosis rather than the slower apoptosis pathway. The peptide has also been reported to disrupt mitochondrial membranes after entering the cell. Normal cells that lack membrane HDM-2 are reported not to bind the peptide and survive, which is the basis for the selectivity claim.

Is PNC27 FDA approved?

No, PNC27 is not currently FDA approved. Current status: Preclinical - Extensive in vitro studies, ex vivo human cancer tissue studies

What are the side effects of PNC27?

Reported side effects include: Limited safety data - research compound only, Highly selective for cancer cells in vitro, No cytotoxicity observed in normal cells (fibroblasts, leukocytes), Temperature-dependent activity (37°C optimal, minimal at 17°C), Not tested in human clinical trials. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of PNC27?

Community-reported common dose: No human dose - research compound only (Not applicable - no human use). Range: Lab research: 0.1-0.3 mg/mL in cell culture. Administration: IV injection in animal studies - not for human use. Research compound only. No human clinical data. Not for human use. Lab research only.

Related Peptides

Peptides commonly compared with PNC27 or used in similar applications.

KPV

Preclinical

KPV is a tiny tripeptide, just three amino acids (lysine, proline, valine), that forms the tail end of the natural hormone alpha-MSH. It is studied almost entirely as an anti-inflammatory agent, particularly for gut and skin inflammation. There are no registered human clinical trials proving its benefits in people; the evidence base is cell-culture and animal studies, so anything you read about it treating disease is preliminary.

Immune

LL-37

Clinical Trials

LL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.

Immune

Thymosin Alpha-1

Clinical Trials

Thymosin alpha-1 (sold as Zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. Unlike most peptides in this space, it is a real, approved drug in over 35 countries for chronic hepatitis B and as an immune booster, though it has never been approved by the FDA in the United States. It has one of the larger human evidence bases of any peptide here, with trials in tens of thousands of patients.

Immune

VIP

Clinical Trials

VIP (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make. It is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil has been tested in humans for COVID-19 respiratory failure and pulmonary conditions. No VIP product is FDA-approved for the wellness or anti-aging uses it gets marketed for, and most of that human data is in lung disease, not in healthy people.

Immune

Enfuvirtide

FDA

Enfuvirtide (brand name Fuzeon, originally T-20) is a 36-amino-acid synthetic peptide and the first HIV fusion inhibitor, FDA-approved in March 2003. It is a genuine prescription antiretroviral, not a research-only compound, and it is given as a twice-daily subcutaneous injection. Its job is narrow but important: it blocks HIV from entering a host cell in the first place, and it is reserved for people whose virus has stopped responding to other drugs.

Immune

Thymogen

Clinical Trials

Thymogen is the brand name for L-Glu-L-Trp (glutamyl-tryptophan, the dipeptide EW), an immune-modulating peptide isolated from the calf thymus extract Thymalin. It is the smallest active piece of that thymic complex and is studied for boosting T-cell activity and immune function. It has been used clinically in Russia since 1990 but has never been evaluated or approved by any Western regulator, and rigorous independent trials are lacking.

Immune

Want updates on PNC27 research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.